Xiaoqin Lu
Chief Strategy OfficerDr. Xiaoqin Lu, also known as Lucy, M.D., is Chief Strategy Officer of Fortress Biotech, Inc. from April 21, 2025. She served as Director at Fortress Biotech, Inc. since December 14, 2022 until April 15, 2025. She serves as Independent Director at Veru Inc. since May 14, 2021. She had been Chief Executive Officer and President of Avenue Therapeutics, Inc., since June 2, 2017 until March 31, 2022 and served as its Interim Chief Financial Officer since January 07, 2022. At Avenue, where she co-invented the foundational U.S. patents for intravenous tramadol, led its Nasdaq initial public offering and directed the clinical development program including two successful Phase 3 studies. She served as Interim Chief Executive Officer and Interim President of Avenue Therapeutics, Inc., from February 2015 to June 2, 2017. She served as a Director of Avenue Therapeutics, Inc. since 2015 until March 31, 2022. Dr. Lu is the Chief Operations Officer at Innovative Cellular Therapeutics since April 2022. Dr. Lu served as the Chief Financial Officer and Executive Vice President at Fortress Biotech, Inc. (formerly known as Coronado Biosciences, Inc.) from February 22, 2012 to June 26, 2017. Dr. Lu has experience wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies. Most recently, Dr. Lu served as a Senior Biotechnology Analyst at Citigroup Inc, Investment Research Division from February 2007 to January 2012, where she was responsible for the coverage of small and middle capitalization stocks and the vetting of both public and private companies. Dr. Lu served as Vice President and Principal at Broadpoint AmTech Inc. Dr. Lu served as Vice President at First Albany Capital since April 2004 until February 2006 and served as its Principal since February 2006. Dr. Lu was employed at Broadpoint Capital Inc., Research Division. She started her career as an Associate of Healthcare Investment Banking at Lehman Brothers Holdings Inc. She was an Independent Director of Inventiva S.A. since May 29, 2018 until 2025. She was a Director of Veru, Inc (Formerly known as Female Health Company) since October 31, 2016 until March 2019. She has served as a Member of the Board of Directors of Iventia Healthcare Limited since 2018. She has leadership & management experience, understanding of biopharmaceutical companies and extensive knowledge of business & industry. She holds an M.D. degree from the New York University School of Medicine; an M.B.A. from the Leonard N. Stern School of Business at New York University; and a B.A. from the University of Tennessee's College of Arts and Science.
Positions
- Company NameFortress Biotech, Inc.Stock CodeFBIOPositionChief Strategy OfficerRelated SecuritiesColleagues
- Company NameVeru Inc.Stock CodeVERUPositionIndependent DirectorColleagues
- MSMitchell S. SteinerChairman, President & CEO
- HDHarry D. FischVice Chairman & Chief Corporate Officer
- KGK. Gary BarnetteChief Scientific Officer
- MGMichele GrecoCFO & Chief Administrative Officer
- SFSamuel FischExecutive Director of Investor Relations & Corporate Communications
- LJLouis J. AronneChief Medical Advisor & Member of the Scientific Advisory Board
- XLXiaoqin LuIndependent Director
- MLMichael L. RankowitzIndependent Director
